title: A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia.
abstract: Thirteen patients with accelerated phase of chronic myeloid leukemia (CML-AC) were treated with intravenous plicamycin and subcutaneous alpha-interferon. Two patients stabilized, three patients had partial hematologic responses and one patient had a hematologic complete response with a major cytogenetic response. Two patients, progressing on hydroxyurea, did not respond, but demonstrated re-sensitization to hydroxyurea after completion of induction therapy and had prolonged return to chronic phase for 30 months and 25 months. Four non-responders subsequently received additional chemotherapy and responded. Median survival of all study patients from the development of accelerated phase of CML was 24 months: substantially longer than other reported series (median 6 months). Plicamycin appears to add efficacy to interferon in the stabilization of accelerated phase of CML.
authors.affiliation: Department of Oncology, Montefiore Medical Center/Albert Einstein Cancer Center, Bronx, NY 10467, USA.
authors.forename: J P
authors.initials: JP
authors.lastname: Dutcher
authors.forename: D
authors.initials: D
authors.lastname: Coletti
authors.forename: E
authors.initials: E
authors.lastname: Paietta
authors.forename: P H
authors.initials: PH
authors.lastname: Wiernik
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D008926:Plicamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D015996:Survival Rate
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D008926:Plicamycin; D006918:Hydroxyurea